Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 5;12:808. doi: 10.1038/s41467-021-21068-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — OS on ICI compared to non-ICI in the a Harvard, b IMDC and c CheckMate S/R RCC cohorts. TTF on ICI compared to non-ICI in the d Harvard and e IMDC S/R RCC cohorts and f PFS in the CheckMate S/R RCC cohort. g Summary table of overall response rate (among evaluable patients) on ICI compared to non-ICI in patients with S/R RCC across the Harvard, IMDC, and CheckMate cohorts. 95% CI: 95% Confidence Interval; Adj. Adjusted; Ever: Everolimus; HR: Hazard Ratio; ICI: Immune Checkpoint Inhibitor; IMDC: International Metastatic Renal Cell Carcinoma Database Consortium; Nivo: Nivolumab; NE: Not Evaluable; OS: Overall Survival; S/R: Sarcomatoid/Rhabdoid. *Adjusted for IMDC (International Metastatic Renal Cell Carcinoma Database Consortium) risk groups, line of therapy, and background histology. **Adjusted for MSKCC (Memorial Sloan Kettering Cancer Center) risk groups.